FY2019 EPS Estimates for TG Therapeutics Inc (TGTX) Cut by Cantor Fitzgerald

Share on StockTwits

TG Therapeutics Inc (NASDAQ:TGTX) – Equities researchers at Cantor Fitzgerald reduced their FY2019 earnings per share (EPS) estimates for TG Therapeutics in a note issued to investors on Tuesday, May 14th. Cantor Fitzgerald analyst A. Young now anticipates that the biopharmaceutical company will earn ($1.64) per share for the year, down from their previous estimate of ($1.57). Cantor Fitzgerald has a “Buy” rating and a $17.00 price objective on the stock.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.01. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%.

TGTX has been the topic of a number of other reports. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. Zacks Investment Research lowered TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of TG Therapeutics in a research note on Friday, April 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of TG Therapeutics in a research note on Wednesday, February 6th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $14.07.

TG Therapeutics stock opened at $6.92 on Friday. The company has a quick ratio of 2.03, a current ratio of 1.72 and a debt-to-equity ratio of 1.89. TG Therapeutics has a one year low of $3.32 and a one year high of $16.00.

A number of hedge funds have recently modified their holdings of the business. Advisor Group Inc. increased its holdings in TG Therapeutics by 23.6% in the first quarter. Advisor Group Inc. now owns 7,850 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,500 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its holdings in TG Therapeutics by 46.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 2,200 shares in the last quarter. Teachers Advisors LLC increased its holdings in TG Therapeutics by 4.3% in the third quarter. Teachers Advisors LLC now owns 127,405 shares of the biopharmaceutical company’s stock worth $713,000 after purchasing an additional 5,221 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in TG Therapeutics by 10.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 71,312 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 6,812 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in TG Therapeutics by 1.0% in the first quarter. Northern Trust Corp now owns 809,943 shares of the biopharmaceutical company’s stock worth $6,512,000 after purchasing an additional 8,383 shares in the last quarter. Institutional investors and hedge funds own 55.26% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Recommended Story: Different Options Trading Strategies

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Expect Bank of Hawaii Co.  to Announce $1.38 Earnings Per Share
Analysts Expect Bank of Hawaii Co. to Announce $1.38 Earnings Per Share
Soarcoin 1-Day Trading Volume Tops $220.00
Soarcoin 1-Day Trading Volume Tops $220.00
Mason Graphite  Shares Up 5.6%
Mason Graphite Shares Up 5.6%
Continental Gold  Shares Up 0.7%
Continental Gold Shares Up 0.7%
Arcus Biosciences Inc  Short Interest Update
Arcus Biosciences Inc Short Interest Update
Hancock Whitney Corp  Given Average Rating of “Buy” by Analysts
Hancock Whitney Corp Given Average Rating of “Buy” by Analysts


 
© 2006-2019 Zolmax.